Dana-Farber Cancer Institute
Avatar

DFCI's ASCO 2019 Update: Review of FDA's Approval of the First Targeted Agent for Metastatic Urothelial Carcinoma - FGFRi Erdafitinib

By Dana-Farber Cancer Institute FEATURING Guru Sonpavde
By Dana-Farber Cancer Institute FEATURING Guru Sonpavde
1,649 views
June 24, 2019
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
15:58
Total Health

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Feat. M. Reimers
19:30
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Sequencing 1L Therapies in Metastatic Urothelial Carcinoma

Feat. P. Grivas
11:29
Oncology Data Advisor

Enfortumab Vedotin + Pembro for Previously Untreated Advanced Urothe…

Feat. T. Powles
12:14
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Sequencing 2L & Later Line Therapies in Metastatic Urothelial Ca…

Feat. P. Grivas
42:02
PleXus Communications

Improving Bladder Cancer Outcomes by Integrating New Knowledge Into …

Feat. M. Galsky
20:33
Arlene Siefker-Radtke

Selection and Sequencing: Emerging Therapy in Metastatic Urothelial …

14:25
GRACE

The Role of ctDNA Biomarker in Bladder Cancer

Feat. J. Brown
11:56
PROSCA & BLADDR 2023

mUC Data With an Impact on Clinical Practice

Feat. D. De Maeseneer
21:32
ASCO 2022 Conference Coverage

ASCO 2022 Bladder Cancer Highlights

Feat. G. Sonpavde
34:37
Community Oncology Alliance

Updates in Genitourinary Malignancies

Feat. M. Lattanzi
09:30
PROSCA & BLADDR 2023

A New SOC in 1L Treatment of mUC?

Feat. I. Durán, D. Castellano
10:38
PROSCA & BLADDR 2023

Best Practices for mUC: Defining & Treating Oligometastatic Blad…

Feat. P. Hoskin
22:00
ecancer

ESMO 2023 Insights: "A Biomarker-Led Approach to Bladder Cancer…

Feat. A. Necchi, G. De Velasco, A. Siefker-Radtke, Y. Loriot
04:18
GRACE

Cisplatin-Ineligible Treatment Options for Advanced Bladder Cancer

Feat. J. Brown
34:35
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Approaches to the Patient With Advanced Urothelial Cancer

Feat. J. Hoffman-Censits
08:22
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzum…

Feat. S. Tagawa
02:11
GRACE

Future Trends for Bladder Cancer Treatment

Feat. J. Brown
19:48
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023

Feat. C. Mantia, J. Bellmunt
06:53
Mirrors of Medicine

AVENANCE Real-World Study Updates: 1L Avelumab Maintenance Treatment…

Feat. P. Barthelemy
17:39
Mirrors of Medicine

More Real-World Evidence on Avelumab Outcomes in Bladder Cancer

Feat. M. De Santis, P. Grivas